Fluphenazine was the first long-acting injectable antipsychotic and established the LAI strategy that modern psychiatry now relies on. The pharmacology is high-potency FGA — pure D2 antagonism, similar profile to haloperidol — but the formulation strategy is what made it transformative.
- Class
- High-potency first-generation antipsychotic
- Mechanism
- Potent D2 antagonism; minimal H1, M1, alpha-1 effects
- Typical dose
- PO 1-40 mg/day; decanoate 12.5-50 mg IM every 2-4 weeks
- Half-life
- PO ~15 hours; decanoate ~7-10 days
- FDA indications
- Schizophrenia, chronic psychotic disorders
- Key adverse effects
- EPS (acute dystonia, akathisia, parkinsonism, TD), hyperprolactinemia, NMS
Black box: Increased mortality in elderly patients with dementia-related psychosis
Decanoate formulation historically a workhorse for adherence-limited schizophrenia. Largely replaced by SGA LAIs (paliperidone palmitate, aripiprazole) where available and affordable. Still used in cost-constrained settings.
The decanoate ester is a slow-release formulation injected intramuscularly in oily depot. After injection, the ester is slowly hydrolyzed, releasing active drug over weeks. A single intramuscular dose of 12.5 to 50 milligrams given every two to four weeks maintains therapeutic plasma levels. Adherence becomes a formulation property rather than a daily patient decision.
For adherence-limited schizophrenia — patients whose insight is limited, whose disorganization makes daily dosing impossible, whose social situation interrupts oral regimens — this was a revolution. The patient who comes once a month for an injection gets medication delivery without the daily friction.
Fluphenazine is a high-potency FGA, similar to haloperidol, valued especially in its long-acting decanoate formulation for chronic psychosis.
Mechanism note: Fluphenazine's role mirrors haloperidol's — potent antipsychotic effect with high EPS burden — and its decanoate depot is a long-standing tool for adherence in chronic psychosis.
The cost is the FGA profile. Fluphenazine carries the full EPS burden of high-potency D2 antagonism — acute dystonia, akathisia, parkinsonism, tardive dyskinesia. Prolactin elevation is meaningful. The receptor profile that makes haloperidol useful for rapid IM agitation control also makes long-term fluphenazine maintenance an EPS-heavy choice.
- Cost
- Oral generic: ~$15-40/month. Decanoate ~$30-80/dose.
- Generic status
- Generic for decades.
- Formulary typical
- Tier 1 generic.
- Access friction
- Decanoate availability varies by pharmacy; clinic-administered IM is common. Largely supplanted by SGA LAIs where available.
Prescriber tip: When SGA LAI access or cost is the issue, fluphenazine decanoate remains a usable option. Confirm pharmacy/clinic can obtain.
Today, SGA long-acting injectables — paliperidone palmitate, aripiprazole maintena, risperidone consta — have largely supplanted fluphenazine decanoate. SGA LAIs deliver similar adherence benefit with less EPS, less prolactin elevation, and arguably better long-term tolerability. Fluphenazine remains useful in cost-constrained settings, in patients with established response, and where SGA LAIs are unavailable. The LAI principle that fluphenazine established now reaches more patients through better-tolerated agents.